Loading
CD25 is the part of the interleukin-2 receptor found on activated T cells and on some lymphoma cells; denileukin diftitox uses it as a doorway to deliver a toxin. This dossier gathers the 2 products (1 approved), 4 trials, 0 pathways and 0 resistance routes in the corpus that involve it, with external identifiers so it can be joined to UniProt, ChEMBL, Open Targets and the rest of biology.
CD25 confers high-affinity IL-2 binding; its density on regulatory T cells makes it a candidate for depleting immunosuppressive cells in the tumour microenvironment.
| Cancer | Prevalence | Measure | Note | Source |
|---|---|---|---|---|
| Peripheral T-cell lymphomas | 86% | IHC (anti-Tac), IL-2 receptor in >10% of cells, 13 peripheral T-cell lymphomas | Strauchen and Breakstone 1987; in cutaneous T-cell lymphoma Jones 2004 found strong CD25 in 13 of 17 skin biopsies with lower expression in paired lymph nodes (doi:10.1158/1078-0432.CCR-0721-03) | PMC |
| Hodgkin lymphoma | 58% | IHC (anti-Tac), IL-2 receptor in >10% of cells, 12 Hodgkin's disease cases | Strauchen and Breakstone 1987 (Am J Pathol), 166-case series; positivity includes Reed-Sternberg cells | PMC |
Approximate, population-level figures; the measure column says what was counted. Ranges show the midpoint as a bar.
| Modality | Approved | Phase 3 |
|---|---|---|
| Bispecific antibody 1 | - | |
| IL-2 receptor-directed cytotoxin 1 | - |
| Trial | Setting | Result | Products | ||
|---|---|---|---|---|---|
| 3 | Recruiting | A Randomized, Open Label, Multicenter, Phase 3 Trial Evaluating the Efficacy and Safety of TAK-928 Versus Docetaxel in Participants With Unresectable Locally Advanced or Metastatic Non-Small Cell Lung Cancer With Disease Progression on or After Platinum-Based Chemotherapy and Anti-PD-1/PD-L1 Immunotherapy | - | ||
| 2 | Completed | A Phase II Open-Label, Multicenter Study of Denileukin Diftitox in Patients With Stage IIIC and Stage IV Melanoma | - | ||
| 2 | Completed | Phase II Trial of ONTAK With Metastatic Melanoma | - | ||
| 2 | Completed | A Phase II Trial of Intravenous Ontak to Treat Epithelial Ovarian Cancer FIGO Stage III or Stage IV, or Extraovarian Peritoneal Carcinoma, of Fallopian Tube Carcinoma Failing or Ineligible for First-Line Therapy | - |
No recorded escape route names this target.
No pathway diagram carries this target as a node.
No companion diagnostic in the registry measures this target.
No model entry for this target yet; check the cancer entries on the models page.
No open questions recorded for this target yet. Suggest one.
Query for this target: (TITLE:"CD25" OR ABSTRACT:"CD25" OR TITLE:"IL-2 receptor alpha" OR ABSTRACT:"IL-2 receptor alpha" OR TITLE:"IL2RA" OR ABSTRACT:"IL2RA") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about CD25 (IL-2 receptor alpha), not a curated reading list.
The dossier as machine-readable JSON, at /api/v1/dossiers/cd25.json: identifiers from HGNC, Ensembl, UniProt and ChEMBL, products with status, trials, pathways, hotspots, open questions and assays. The full entity record is in the open API at /api/v1/entities/cd25.json. Licence CC BY-NC 4.0.